IMNM
Immunome, Inc. NASDAQ Listed Oct 2, 2020$19.33
After hrs
$19.28
-0.24%
Mkt Cap $1.7B
52w Low $8.40
58.9% of range
52w High $26.97
50d MA $21.44
200d MA $19.43
P/E (TTM)
-8.1x
EV/EBITDA
—
P/B
2.7x
Debt/Equity
0.0x
ROE
-33.5%
P/FCF
-8.4x
RSI (14)
49.90
ATR (14)
$0.79
Beta
2.14
50d MA
$21.44
200d MA
$19.43
Avg Volume
1.4M
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
665 Stockton Drive · Bothell, PA 19341 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -0.59 | -0.75 | -27.1% | 21.54 | +2.1% | +4.5% | -7.0% | +0.4% | +1.4% | +2.5% | — |
| Nov 6, 2025 | AMC | -0.57 | -0.65 | -14.0% | 15.50 | -0.3% | -1.7% | +7.9% | +6.6% | -0.5% | -5.3% | — |
| Aug 6, 2025 | AMC | -0.52 | -0.50 | +3.8% | 10.46 | +2.4% | -5.6% | -1.8% | -0.3% | +2.6% | +1.0% | — |
| May 12, 2025 | AMC | -0.66 | -0.52 | +21.2% | 7.94 | +5.4% | -0.4% | +0.8% | +0.4% | +0.7% | -0.6% | — |
| Mar 19, 2025 | AMC | -0.68 | -0.84 | -23.5% | 8.57 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% | — |
| Nov 13, 2024 | AMC | -0.60 | -0.78 | -30.0% | 11.59 | -0.2% | -3.9% | -11.1% | -4.6% | -0.5% | -0.6% | — |
| Aug 12, 2024 | AMC | -0.38 | -0.49 | -28.9% | 12.64 | +0.8% | +7.0% | -0.2% | +3.3% | -3.0% | +5.7% | — |
| May 14, 2024 | AMC | -0.80 | -0.34 | +57.5% | 14.72 | +1.4% | +0.5% | -2.7% | -4.0% | -0.2% | -1.1% | — |
| Mar 28, 2024 | AMC | -0.28 | -0.54 | -92.9% | 24.68 | +0.5% | -10.4% | -3.3% | +1.0% | -6.2% | +0.0% | — |
| Nov 9, 2023 | AMC | -0.17 | -0.36 | -111.8% | 8.56 | -1.4% | -5.5% | +1.9% | -2.7% | -0.9% | -0.3% | — |
| Aug 9, 2023 | AMC | -0.16 | -0.46 | -187.5% | 7.04 | +0.7% | +0.1% | +3.0% | -1.9% | +4.5% | -2.0% | — |
| May 5, 2023 | AMC | 0.59 | -0.35 | -159.3% | 5.40 | +0.9% | +6.7% | +8.5% | +0.8% | +1.0% | +7.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28 | Barclays | Initiates | Overweight | $36 | $22.11 | $22.38 | +1.2% | +1.9% | -3.1% | -4.8% | -6.9% | +2.4% |
| Mar 4 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.54 | $22.00 | +2.1% | +4.5% | -7.0% | +0.4% | +1.4% | +2.5% |
| Mar 4 | Craig-Hallum | Maintains | Buy → Buy | — | $21.54 | $22.00 | +2.1% | +4.5% | -7.0% | +0.4% | +1.4% | +2.5% |
| Jan 15 | Wedbush | Maintains | Outperform → Outperform | — | $20.76 | $20.61 | -0.7% | +10.1% | -1.9% | +6.6% | +4.1% | +3.8% |
| Dec 16 | Lake Street | Maintains | Buy → Buy | — | $22.64 | $22.88 | +1.1% | +3.7% | -15.8% | +0.9% | +7.5% | +2.8% |
| Dec 16 | Guggenheim | Maintains | Buy → Buy | — | $22.64 | $22.88 | +1.1% | +3.7% | -15.8% | +0.9% | +7.5% | +2.8% |
| Dec 16 | Evercore ISI | Maintains | Outperform → Outperform | — | $22.64 | $22.88 | +1.1% | +3.7% | -15.8% | +0.9% | +7.5% | +2.8% |
| Nov 17 | Stephens & Co. | Maintains | Overweight → Overweight | — | $17.14 | $17.71 | +3.3% | +5.8% | -1.5% | -1.0% | -1.0% | +5.8% |
| Aug 25 | Guggenheim | Maintains | Buy → Buy | — | $10.30 | $10.30 | +0.0% | -3.7% | +2.4% | -2.1% | -0.5% | -3.9% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $10.46 | $10.71 | +2.4% | -5.6% | -1.8% | -0.3% | +2.6% | +1.0% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $8.57 | $8.42 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% |
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $8.57 | $8.42 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% |
| Mar 20 | Stephens & Co. | Maintains | Overweight → Overweight | — | $8.57 | $8.42 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.59 | $11.57 | -0.2% | -3.9% | -11.1% | -4.6% | -0.5% | -0.6% |
| Oct 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.01 | $12.10 | +0.7% | +0.8% | +2.6% | -1.9% | +0.0% | -6.0% |
| Aug 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.64 | $12.74 | +0.8% | +7.0% | -0.2% | +3.3% | -3.0% | +5.7% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $12.64 | $12.74 | +0.8% | +7.0% | -0.2% | +3.3% | -3.0% | +5.7% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $24.68 | $24.81 | +0.5% | -10.4% | -3.3% | +1.0% | -6.2% | +0.0% |
| Jan 23 | Wedbush | Maintains | Outperform → Outperform | — | $15.65 | $15.92 | +1.7% | -4.2% | +2.2% | +7.0% | +6.6% | +10.4% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.69 | $5.63 | -1.1% | -0.7% | -0.9% | -4.1% | -3.9% | -1.4% |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | $5.14 | $5.02 | -2.4% | +10.6% | -0.7% | -0.9% | -4.1% | -3.9% |
| Oct 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.85 | $23.30 | +2.0% | +2.6% | -5.0% | +2.8% | -4.1% | +3.1% |
| Oct 27 | Chardan Capital | Maintains | Buy → Buy | — | $12.20 | $12.49 | +2.4% | +2.5% | -8.0% | +0.4% | -1.7% | -3.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Rosett Max | Chief Financial Officer | Sell | 60,000 | $18.23 | $1.1M | 54,037 | +1.13% | — |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Buy | 1,000 | $19.27 | $19K | 43,415 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Buy | 3,500 | $19.46 | $68K | 42,415 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Buy | 6,000 | $19.48 | $117K | 38,915 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Sell | 10,000 | $19.41 | $194K | 32,915 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Sell | 500 | $19.44 | $10K | 42,915 | -1.25% | -0.89% |
| May 15, 2026 | BIENAIME JEAN JACQUES | — | Buy | 5,000 | $20.70 | $104K | 43,415 | +9.51% | +0.91% |
8-K · 2.02
!! High
Immunome, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K
Immunome, Inc. -- 8-K Filing
Immunome reported 2025 full-year financial results and provided a business update on its pipeline of targeted cancer therapies, though specific revenue or clinical milestone details require review of the complete filing.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 16,969,954 | $371M | Added | Mar 2026 |
| 2 | Primecap Management Co/ca/ | 4,788,231 | $105M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 4,429,697 | $97M | New | Mar 2026 |
| 4 | Morgan Stanley | 3,418,178 | $73M | Reduced | Dec 2025 |
| 5 | Jpmorgan Chase & Co | 2,777,836 | $54M | Reduced | Mar 2026 |
| 6 | Woodline Partners Lp | 1,575,398 | $34M | — | Mar 2026 |
| 7 | Marshall Wace, Llp | 1,480,788 | $32M | Added | Mar 2026 |
| 8 | Principal Financial Group Inc | 1,404,450 | $30M | Added | Dec 2025 |
| 9 | Silverarc Capital Management, Llc | 1,126,210 | $24M | New | Dec 2025 |
| 10 | Bnp Paribas Asset Management Holding S.a. | 1,097,836 | $24M | Added | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 1,006,975 | $22M | New | Mar 2026 |
| 12 | Northern Trust Corp | 899,146 | $20M | Added | Mar 2026 |
| 13 | Janus Henderson Group Plc | 808,019 | $18M | New | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 781,607 | $17M | Added | Mar 2026 |
| 15 | Nan Fung Trinity (Hk) Ltd | 714,553 | $16M | — | Mar 2026 |
| 16 | Candriam S.c.a. | 539,882 | $12M | Reduced | Dec 2025 |
| 17 | Ubs Group Ag | 432,912 | $9M | Added | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 362,621 | $8M | Added | Mar 2026 |
| 19 | Atom Investors Lp | 306,880 | $7M | Added | Mar 2026 |
| 20 | Nuveen, Llc | 305,254 | $7M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.69B
Enterprise Value
$1.04B
P/E (TTM)
-8.09x
Forward P/E
—
PEG Ratio
0.17x
P/B
2.66x
P/S
420.55x
P/FCF
-8.42x
EV/EBITDA
—
Shares Out
87.4M
Financials (TTM)
Revenue
$4.0M
Net Income
-$224.6M
EBITDA
-$221.8M
Free Cash Flow
-$200.6M
Op Cash Flow
-$190.9M
EPS Basic
$-2.43
EPS Diluted
$-2.39
EPS Forward
$-2.40
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$683.2M
Total Liab.
$48.8M
Total Equity
$634.3M
Cash
$653.5M
LT Debt
$3.9M
Book Value/Sh
$7.26
Debt/Equity
0.01x
Current Ratio
14.69
Quick Ratio
14.69
Returns & Growth
ROE
-33.5%
ROA
-31.1%
ROIC
-33.6%
Rev Growth YoY
-23.2%
EPS Growth YoY
+51.4%
Price Returns
2W
-0.9%
1M
-4.8%
3M
-0.1%
6M
+18.5%
12M
+149.2%
Technicals
52W High
$26.97
52W Low
$8.40
50d MA
$21.44
200d MA
$19.43
RSI (14)
49.90
ATR (14)
$0.79
Beta
2.14
Avg Volume
1.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$36.83
High
$40.00
Low
$32.00
Median
$38.00
Data updated apr 25, 2026 3:19pm
· Source: financialmodelingprep.com